Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation.
By T. Rand, S. Petersen, Fenghe Du, Xiaodong Wang. Cell, 2005
851 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/d8ef38b34d69e6d3a1a0d3381f35621ed4585837
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- P. Murphy
- Leigh-Ann MacFarlane
- T. Rana
- Thomas Tuschl
- Gregory J. Hannon
- Joshua T. Mendell
- John J. Rossi
- Richard W. Carthew
In Molecular Biology
- T. Rana
- John J. Rossi
- Gregory J. Hannon
- Thomas Tuschl
- P. Murphy
- Leigh-Ann MacFarlane
- Daniel H. Kim
- Joshua T. Mendell
Citations in the corpus
- MicroRNAs in cell proliferation, cell death, and tumorigenesis (2006, background): “Nevertheless, the broad significance of these findings was not fully appreciated until hundreds of similar small RNAs were identified in C. elegans, Drosophila, and mammals by molecular cloning and bioinformatics analyses in 2001 (reviewed in Bartel, 2004).”
- Strategies for silencing human disease using RNA interference (2007, background): “RISC activation is initially thought to involve AGO2-mediated cleavage of the sense or passenger strand of the double-stranded siRN”
- Human tRNA-derived small RNAs in the global regulation of RNA silencing. (2010, background): “It is then the ability of Ago2 to rapidly cleave the passenger strand (Matranga et al. 2005; Rand et al. 2005) of asymmetric siRNAs that is ultimately responsible for the observed strand bias.”
- RNAi therapeutics: a potential new class of pharmaceutical drugs (2006, background): “For example, siRNAs conjugated with cholesterol improve in vitro and in vivo cell permeation in liver cells 6 .”
- siRNA vs. shRNA: similarities and differences. (2009, background): “endonuclease activity necessary to cleave and release the passenger strand of the double-stranded stem [76,77,79].”
- Current prospects for RNA interference-based therapies (2011, background): “One strand is the 'guide' strand and directs silencing, with the other strand -the 'passenger' -being degraded 22, 23 .”
- MicroRNA: Biogenesis, Function and Role in Cancer (2010, methodology): “The process of miRNA duplex unwinding and subsequent degradation is similar to siRNA, where Ago2 cleavage of the passenger strand releases single strand mature miRNA to function in RISC [19, 20, 33, 60-62, 76, 126, 139-142, 146, 147].”